Randomised, Embedded, Multi-factorial, Adaptive Platform Trial for Community-Acquired Pneumonia

Ziauddin University has signed a Research Collaboration Agreement with Monash University, Australia to implement the global “Randomised, Embedded, Multi-factorial, Adaptive Platform Trial for Community-Acquired Pneumonia” (REMAP-CAP) project. REMAP-CAP is a global network of leading experts, institutions and research networks. With over 250 participating world-wide, REMAP-CAP is a truly global trial.

It is an adaptive platform trial in community acquired pneumonia, that was specifically designed to be employed in a pandemic to evaluate multiple interventions simultaneously in critically ill patients. In addition to recruiting patients with community acquired pneumonia who have been admitted to critical care, we are also recruiting patients with COVID-19 to understand optimal treatment strategies.

Ziauddin University is also the coordinating centre for other partner sites in Pakistan, including NICVD, The Indus Hospital, South City Hospital. The sites are increasing as the project progresses. The project is funded by Monash University.


Dr Madiha Hashmi’s efforts for bringing these global collaborations to Ziauddin University are highly laudable and continuous support from University Leadership is greatly appreciated.